Welcome to the Swiss Peritoneal Cancer Group
The Swiss Peritoneal Cancer Group (SPCG) was founded in June 2013 and two years later the group was accepted as a workgroup of the Swiss Society for Visceral Surgery (Schweizerische Gesellschaft für Viszeralchirurgie, SGVC). The SPCG provides a platform for surgeons, gynecologists and medical oncologists engaged in peritoneal malignancies, cytoreduction and HIPEC.
March 8 – 9, 2018
Hotel Congress Einstein, St.Gallen
Swiss Peritoneal Cancer Group
The aims and tasks of the SPCG are:
- One meeting per year
- General assembly during the congress of the Swiss Society for Surgery (Schweizerische Gesellschaft für Chirurgie, SGC) or during a congress of the Swiss Society for Visceral Surgery (Schweizerische Gesellschaft für Viszeralchirurgie, SGVC)
- Establishing a Swiss registry for cytoreduction/HIPEC
- Organization and realization of a regular congress on cytoreduction/HIPEC in Switzerland
- Promotion of research in the field of cytoreduction/HIPEC
We are proud to present to you the current list of responsibilities in the SPCG.
Board member SGVC
Science / data management
Swiss Society of Visceral Surgery
The society aims to promote visceral surgery in cooperation with and within the Swiss Society of Surgery (Schweizerische Gesellschaft für Chirurgie, SGC). It deals primarily with health policy issues, professional policy aspects, problems and quality of education and training as well as certification requirements. The society represents the interests of visceral surgeons in professional organizations and in collective bargaining. The group collaborates with European professional societies with the same or similar interests and can join such societies as a member.
Crohn’s disease-associated large and small bowel adenocarcinoma with peritoneal carcinomatosis: two case reports.
Kobe A, Posabella A, Tampakis A, von Fluee M, Bolli M.
Int J Colorectal Dis. 2016 Mar 7. [Epub ahead of print]
Where Oncologic and Surgical Complication Scoring Systems Collide: Time for a New Consensus for CRS/HIPEC.
Lehmann K, Eshmuminov D, Slankamenac K, Kranzbühler B, Clavien PA, Vonlanthen R, Gertsch P.
World J Surg. 2016 May;40(5):1075-81. doi: 10.1007/s00268-015-3366-0.
Hepatic resection during cytoreductive surgery for primary or recurrent epithelial ovarian cancer.
Gasparri ML, Grandi G, Bolla D, Gloor B, Imboden S, Panici PB, Mueller MD, Papadia A.
J Cancer Res Clin Oncol. 2015 Dec 11. [Epub ahead of print]
Incorporation of postoperative CT data into clinical models to predict 5-year overall and recurrence free survival after primary cytoreductive surgery for advanced ovarian cancer.
Burger IA, Goldman DA, Vargas HA, Kattan MW, Yu C, Kou L, Andikyan V, Chi DS, Hricak H, Sala E.
Gynecol Oncol. 2015 Sep;138(3):554-9. doi: 10.1016/j.ygyno.2015.06.010. Epub 2015 Jun 17.
Hyperthermia-related clinical trials on cancer treatment within the ClinicalTrials.gov registry.
Cihoric N, Tsikkinis A, van Rhoon G, Crezee H, Aebersold DM, Bodis S, Beck M, Nadobny J, Budach V, Wust P, Ghadjar P.
Int J Hyperthermia. 2015 Sep;31(6):609-14. doi: 10.3109/02656736.2015.1040471. Epub 2015 May 15.
Peritoneal carcinomatosis in primary ovarian cancer staging: comparison between MDCT, MRI, and 18F-FDG PET/CT.
Schmidt S, Meuli RA, Achtari C, Prior JO.
Clin Nucl Med. 2015 May;40(5):371-7. doi: 10.1097/RLU.0000000000000768.
Proceedings of the 9th International Congress on Peritoneal Surface Malignancies, October 9th – 11th 2014, Amsterdam.
Seretis C, Shariff U, Raju T, Halkia E, Spiliotis J, Youssef H.
J BUON. 2015 Jan-Feb;20(1):346-7. No abstract available.
Anaesthesia in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: retrospective analysis of a single centre three-year experience.
Kajdi ME, Beck-Schimmer B, Held U, Kofmehl R, Lehmann K, Ganter MT.
World J Surg Oncol. 2014 May 1;12:136. doi: 10.1186/1477-7819-12-136.
New insight into hyperthermic intraperitoneal chemotherapy: induction of oxidative stress dramatically enhanced tumor killing in in vitro and in vivo models.
Lehmann K, Rickenbacher A, Jang JH, Oberkofler CE, Vonlanthen R, von Boehmer L, Humar B, Graf R, Gertsch P, Clavien PA.
Ann Surg. 2012 Nov;256(5):730-7; discussion 737-8. doi: 10.1097/SLA.0b013e3182737517.
Does hyperthermic intraoperative chemotherapy lead to improved outcomes in patients with ovarian cancer? A single center cohort study in 111 consecutive patients.
Warschkow R, Tarantino I, Lange J, Müller SA, Schmied BM, Zünd M, Steffen T.
Patient Saf Surg. 2012 Jun 15;6(1):12. doi: 10.1186/1754-9493-6-12.
PMID: 22709648 Free PMC Article
Sirolimus and intraoperative hyperthermic peritoneal chemoperfusion with mitomycin-C do not impair healing of bowel anastomoses.
Wagner OJ, Inglin RA, Bisch-Knaden S, Mettler D, Borner M, Candinas D, Egger B.
Transpl Int. 2008 Jun;21(6):554-63. doi: 10.1111/j.1432-2277.2007.00635.x. Epub 2008 Jan 21.
PMID: 18225992 Free Article
Surgical management of epithelial ovarian cancer at community hospitals: A population-based study.
Petignat P, Vajda D, Joris F, Obrist R.
J Surg Oncol. 2000 Sep;75(1):19-23.
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology.
Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan TD, Alexander R, Baratti D, Bartlett D, Barone R, Barrios P, Bieligk S, Bretcha-Boix P, Chang CK, Chu F, Chu Q, Daniel S, de Bree E, Deraco M, Dominguez-Parra L, Elias D, Flynn R, Foster J, Garofalo A, Gilly FN, Glehen O, Gomez-Portilla A, Gonzalez-Bayon L, Gonzalez-Moreno S, Goodman M, Gushchin V, Hanna N, Hartmann J, Harrison L, Hoefer R, Kane J, Kecmanovic D, Kelley S, Kuhn J, Lamont J, Lange J, Li B, Loggie B, Mahteme H, Mann G, Martin R, Misih RA, Moran B, Morris D, Onate-Ocana L, Petrelli N, Philippe G, Pingpank J, Pitroff A, Piso P, Quinones M, Riley L, Rutstein L, Saha S, Alrawi S, Sardi A, Schneebaum S, Shen P, Shibata D, Spellman J, Stojadinovic A, Stewart J, Torres-Melero J, Tuttle T, Verwaal V, Villar J, Wilkinson N, Younan R, Zeh H, Zoetmulder F, Sebbag G; Society of Surgical Oncology Annual Meeting.
Ann Surg Oncol. 2007 Jan;14(1):128-33. Epub 2006 Oct 28. No abstract available. Erratum in: Ann Surg Oncol. 2011 Dec;18 Suppl 3:S334-5.
To become a member
If you perform HIPEC or related procedures or if you are interested in the treatment of PSM or related procedures we would like to invite you to become a member of the group. As a member you can actively participate in the work of the SPCG and will be informed about the current developments and activities of the Group.
Since we are a workgroup of the SGVC, full membership can only be granted to members of the Swiss Society for Visceral Surgery or the Swiss Society for Surgery. Otherwise holders of an FMH-title or an FMH-equivalent title would be eligible for associate membership (“zugewandte Mitgliedschaft”).
If you are interested to become a member of the Swiss Peritoneal Cancer Group please fill out the form linked on register now and send it directly back per e-mail or to Tanja Burkard. Her contact details can be found below.
The membership fee of the Swiss Peritoneal Cancer Group will be included in the invoice for the membership fee of the Swiss Society for Visceral Surgery (SGVC).
In case you have any questions please do not hesitate to contact Tanja Burkard who will surely help you with your requests.
Kantonsspital St. Gallen
Klinik für Allgemein-, Viszeral-, Endokrin- und Transplantationschirurgie
CH-9007 St. Gallen
Phone: +41 71 494 1344